Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Amgen’s (AMGN) earnings are expected to decline in the third quarter, which is scheduled for November 4, after markets close.

If you're looking at Amgen and wondering whether it's time to buy, hold, or maybe even take profits, you're not alone. The ...

Amgen stock has been underperforming the broader market over the past year, and analysts are adopting a cautiously bullish ...

Amgen's weight management candidate looks very promising. The large biotech boasts a deep pipeline beyond that segment. Amgen's dividend looks great, and the stock is reasonably valued. Even so, there ...

Amgen (AMGN) closed at $280.19 in the latest trading session, marking a -1.22% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.21%. Elsewhere, the Dow saw an ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US drug ...

Amgen Inc. (NASDAQ:AMGN) on Monday launched AmgenNow, a new direct-to-patient program starting with Repatha (evolucumab). AMGN stock is trending lower. View the charts here. This follows results ...

Amgen slashed the price of its cholesterol medication by more than half for U.S. patients through a new medication-access program amid the Trump administration's call to lower drug prices. The ...